We use cookies for a better user experience. Read our Privacy Policy

I Agree

Acute Agitation and Aggression Treatment Market Trends, 2021-2031

Acute Agitation and Aggression Treatment Market (Treatment Approach: Behavioral Approaches, Environmental Interventions, and Pharmacologic Approaches [Drugs]; Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-induced Agitation & Aggression, Alcohol Withdrawal, and Others; Route of Administration: Oral, Intramuscular, and Others; and End-user: Hospitals & Ambulatory Surgical Centers, Psychiatric Care Facilities, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Pharmacies Increase Digital Visibility to Offer Affordable Medications amid Coronavirus Pandemic

Telehealth services and mental health apps are storming the acute agitation and aggression treatment market during the ongoing coronavirus pandemic. Since increasing number of individuals are unable to afford treatment or medications, affordable telehealth services and mental health apps are helping to reduce anxiety among individuals.

Online pharmacies in the acute agitation and aggression treatment market are increasing their visibility digitally to help individuals compare the prices of medications. Manufacturers are maintaining optimum inventory levels to ensure a continuous supply of therapeutics. An increasing number of pharmaceutical companies are providing coupons and price reduction promo codes to help individuals purchase medications. Even insurance providers are refilling the prescription of patients well before the refill date in order to improve patient quality of life.

acute agitation and aggression treatment market infographic

To know the scope of our report Get a Sample on Acute Agitation and Aggression Treatment Market

Research Investment Helps in Development of Well-tolerated Antidepressants

Like all medications, even antidepressants are associated with side effects such as headache, nausea, and insomnia in many cases. Hence, companies in the acute agitation and aggression treatment market are continuously investing in R&D to develop improved formulations of antidepressants. As such, antidepressants such as serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and atypical antidepressants are well-tolerated in individuals.

In order to reduce reliance on antidepressants, healthcare providers are increasing emphasis on behavioral approaches including lifestyle changes, brain stimulation therapies, and integrative medicines in order to improve patient outcomes. There is a growing awareness about different forms of psychotherapy that are helping patients suffering from depression. Cognitive behavioral therapy (CBT), diet changes, and family therapy are being publicized to improve patient quality of life.

Get a glimpse of the in-depth analysis through our Report Brochure

Benzodiazepines Gain Prominence in Emergency Department for Rapid Treatment of Acute Agitation

The acute agitation and aggression treatment market is predicted to expand at a modest CAGR of 5.1% during the forecast period. Manufacturers are increasing the production of benzodiazepines for the rapid treatment of acute agitation in the emergency department (ED). Benzodiazepines are being known for sedating an undifferentiated patient without obvious delirium or psychiatric disease. However, benzodiazepines carry the risk of creating a paradoxical reaction in patients, especially the elderly and young population. As such, it has been found that benzodiazepines are well-tolerated and adverse reactions are rare.

Healthcare providers in the acute agitation and aggression treatment market are increasing awareness that benzodiazepines carry the risk for respiratory depression and hence must be avoided for patients who have ingested other depressant medications.

Lorazepam Being Publicized for Effective Treatment of Acutely Agitated Patients

The acute agitation and aggression treatment market is projected to cross the value of US$ 7.09 Bn by 2031. Acute agitation is a frequent occurrence in both inpatient and outpatient psychiatric settings. This is acting as a key driver for market growth. Manufacturers in the acute agitation and aggression treatment market are increasing their production for Lorazepam, which is a type of benzodiazepine that is being extensively used for the management of acute agitation.

Lorazepam is being publicized as a clinically effective means of treating acutely agitated patients. This medication is being frequently used as the sedative and anxiolytic of choice in inpatient settings due to its rapid onset of action when administered intravenously.

acute agitation and aggression treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Several brick and mortar pharmacies have started offering telemedicine services to help patients stock their medications during the ongoing COVID-19 pandemic. Apart from medications, healthcare providers in the acute agitation and aggression treatment market are providing non-pharmacologic de-escalation techniques including verbal de-escalation, combined with re-orientation and successive attempts at a therapeutic alliance. Sedation related adverse events, owing to medications should be overcome with increased research in well-tolerated therapeutic formulations. Manufacturers are producing Olanzapine for the treatment of agitation meant for intravenous administration. Midazolam, on the other hand, is being made available for intranasal and oral route of administration in acutely agitated patients, especially in EDs.

Acute Agitation and Aggression Treatment Market: Overview

  • This report analyzes the current scenario and future prospects of the global acute agitation and aggression treatment market. Rise in burden of mental illnesses and increase in agitation in patients are projected to boost the growth of the global acute agitation and aggression treatment market.
  • The report includes an elaborate executive summary, which provides a snapshot of various segments of the global acute agitation and aggression treatment market. It also provides information and data analysis of the acute agitation and aggression treatment market about segments based on treatment approach, route of administration, indication, end-user, and region.
  • The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that affect the global acute agitation and aggression treatment market
  • The report includes company profiles, which provide information about their business, product portfolios, and competitive landscape in the global acute agitation and aggression treatment market
  • The report on the acute agitation and aggression treatment market offers market attractiveness analysis of regions and segments
  • The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global acute agitation and aggression treatment market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global acute agitation and aggression treatment market.

Acute Agitation and Aggression Treatment Market: Key Segments

  • In terms of treatment approach, the global acute agitation and aggression treatment market has been classified into behavioral approaches, environmental interventions, and pharmacologic approaches (drugs). The pharmacologic approaches (drugs) segment has been split into lorazepam, chlorpromazine, quetiapine, droperidol, olanzapine, ziprasidone, and others. The pharmacologic approaches (drugs) segment accounted for major share of the market in 2020 and the trend is anticipated to continue during the forecast period. Benefits of drugs such as ease of administration, rapid onset of action, and sufficient duration of effect are expected to boost the demand for pharmacologic approach for agitation and aggression treatment, which in turn is likely to augment the segment.
  • Based on route of administration, the global acute agitation and aggression treatment market has been categorized into oral, intramuscular, and others. The oral segment dominated the market in 2020. Growth of the segment can be attributed to the recommended usage of agitation treatment drugs in oral form.
  • In terms of indication, the global acute agitation and aggression treatment market has been segregated into schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation & aggression, alcohol withdrawal, and others. Rise in prevalence of schizophrenia is projected to drive the schizophrenia segment.
  • Based on end-user, the global acute agitation and aggression treatment market has been divided into hospitals & ambulatory surgical centers, psychiatric care facilities, and others. The hospitals & ambulatory surgical centers segment accounted for major share of the market. Rise in occurrence of agitation in hospitalized patients is anticipated to propel the segment.
  • Market size and forecast for each of these segments have been provided from 2017 to 2031. The CAGR of respective segments has also been provided from 2021 to 2031, considering 2020 as the base year.

Acute Agitation and Aggression Treatment Market: Regional Outlook

  • In terms of region, the global acute agitation and aggression treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region considered in the market has been divided into countries/sub-regions.
  • The acute agitation and aggression treatment market report provides size and forecast for each region and country/sub-region from 2017 to 2031. The CAGR for each of these regions and countries has also been provided for the forecast period from 2021 to 2031. The acute agitation and aggression treatment market study also covers the competitive scenario in these regions.

Companies Covered in Acute Agitation and Aggression Treatment Market Report

  • Key players in the global acute agitation and aggression treatment market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the acute agitation and aggression treatment market report are
    • Eli Lilly and Company
    • Pfizer, Inc.
    • GlaxoSmithKline
    • Otsuka Holdings Co., Ltd.
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd
    • Amneal Pharmaceuticals LLC
    • H. Lundbeck A/S., among others.

Acute Agitation and Aggression Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 4.10 Bn

Market Forecast Value in 2031

US$ 7.09 Bn

Growth Rate (CAGR)

5.1%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

The report scope includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key industry events, product analysis, technological advancement, etc.

Competition Landscape

Company Profiles section includes overview, business overview, strategy & recent developments, key financials, etc.

Format

Electronic (PDF) + Excel

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • Argentina
  • GCC Countries
  • South Africa

Market Segmentation

  • Treatment Approach
    • Behavioral Approaches
    • Environmental Interventions
    • Pharmacologic Approaches (Drugs)
      • Lorazepam
      • Chlorpromazine
      • Quetiapine
      • Droperidol
      • Olanzapine
      • Ziprasidone
      • Others
  • Indication
    • Schizophrenia
    • Dementia
    • Bipolar Disorder
    • Depression
    • Drug-induced Agitation and Aggression
    • Alcohol Withdrawal
    • Others
  • Route of Administration
    • Oral
    • Intramuscular
    • Others
  • End User
    • Hospitals & Ambulatory Surgical Centers
    • Psychiatric Care Facilities
    • Others

Companies Profiled

  • Eli Lilly and Company
  • Pfizer, Inc.
  • Otsuka Holdings
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Apotex, Inc.
  • Aurobindo Pharma

Customization Scope

Available upon request

Pricing

Available upon request

Acute Agitation and Aggression Treatment Market – Segmentation

Treatment Approach
  • Behavioral Approaches
  • Environmental Interventions
  • Pharmacologic Approaches (Drugs)
    • Lorazepam
    • Chlorpromazine
    • Quetiapine
    • Droperidol
    • Olanzapine
    • Ziprasidone
    • Others
Indication
  • Schizophrenia
  • Dementia
  • Bipolar Disorder
  • Depression
  • Drug-induced Agitation & Aggression
  • Alcohol Withdrawal
  • Others
Route of Administration
  • Oral
  • Intramuscular
  • Others
End-user
  • Health Care Providers
  • Psychiatric Care Facilities
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Acute Agitation and Aggression Treatment Market Trends, 2021-2031

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of acute agitation and aggression treatment market?

Acute agitation and aggression treatment market is projected to cross the value of US$ 7.09 Bn by 2031

What is the anticipated CAGR of the acute agitation and aggression treatment market in the forecast period?

Acute agitation and aggression treatment market is predicted to expand at a modest CAGR of 5.1% from 2021 to 2031

What are the key driving factors for the growth of the acute agitation and aggression treatment market?

Acute agitation and aggression treatment market is driven by increase in incidence of dementia in geriatric population

Which region is expected to project the highest market share in the global acute agitation and aggression treatment market?

North America is projected to account for a prominent share of the global acute agitation and aggression treatment market during the forecast period

Who are the key players in the acute agitation and aggression treatment market?

Key players in the global acute agitation and aggression treatment market include Eli Lilly and Company, Pfizer, Inc., GlaxoSmithKline, Otsuka Holdings Co., Ltd., Johnson & Johnson

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Agitation and Aggression Treatment Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Patient journey Analysis

    5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)

    5.4. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

    5.5. Pros and Cons of current Treatment for Acute Agitation and Aggression

    5.6. Technological Advancements

6. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Treatment Approach

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Treatment Approach, 2017–2031

        6.3.1. Behavioral Approaches

        6.3.2. Environmental Interventions

        6.3.3. Pharmacologic Approaches (Drugs)

            6.3.3.1. Lorazepam

            6.3.3.2. Chlorpromazine

            6.3.3.3. Quetiapine

            6.3.3.4. Droperidol

            6.3.3.5. Olanzapine

            6.3.3.6. Ziprasidone

            6.3.3.7. Others

    6.4. Market Attractiveness Analysis, by Treatment Approach

7. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Indication

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Indication, 2017–2031

        7.3.1. Schizophrenia

        7.3.2. Dementia

        7.3.3. Bipolar Disorder

        7.3.4. Depression

        7.3.5. Drug-induced Agitation and Aggression

        7.3.6. Alcohol Withdrawal

        7.3.7. Others

    7.4. Market Attractiveness Analysis, by Indication

8. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Route of Administration, 2017–2031

        8.3.1. Oral

        8.3.2. Intramuscular

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by End-user

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by End-user, 2017–2031

        9.3.1. Hospitals & Ambulatory Surgical Centers

        9.3.2. Psychiatric Care Facilities

        9.3.3. Others

    9.4. Market Attractiveness Analysis, by End-user

10. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness Analysis, by Country/Region

11. North America Acute Agitation and Aggression Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment Approach, 2017–2031

        11.2.1. Behavioral Approaches

        11.2.2. Environmental Interventions

        11.2.3. Pharmacologic Approaches (Drugs)

            11.2.3.1. Lorazepam

            11.2.3.2. Chlorpromazine

            11.2.3.3. Quetiapine

            11.2.3.4. Droperidol

            11.2.3.5. Olanzapine

        11.2.4. Ziprasidone

            11.2.4.1. Others

    11.3. Market Value Forecast, by Indication, 2017–2031

        11.3.1. Schizophrenia

        11.3.2. Dementia

        11.3.3. Bipolar Disorder

        11.3.4. Depression

        11.3.5. Drug-induced Agitation and Aggression

        11.3.6. Alcohol Withdrawal

        11.3.7. Others

    11.4. Market Value Forecast, by Route of Administration, 2017–2031

        11.4.1. Oral

        11.4.2. Intramuscular

        11.4.3. Others

    11.5. Market Value Forecast, by End-user, 2017–2031

        11.5.1. Hospitals & Ambulatory Surgical Centers

        11.5.2. Psychiatric Care Facilities

        11.5.3. Others

    11.6. Market Value Forecast, by Country, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Treatment Approach

        11.7.2. By Indication

        11.7.3. By Route of Administration

        11.7.4. By End-user

        11.7.5. By Country

12. Europe Acute Agitation and Aggression Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment Approach, 2017–2031

        12.2.1. Behavioral Approaches

        12.2.2. Environmental Interventions

        12.2.3. Pharmacologic Approaches (Drugs)

            12.2.3.1. Lorazepam

            12.2.3.2. Chlorpromazine

            12.2.3.3. Quetiapine

            12.2.3.4. Droperidol

            12.2.3.5. Olanzapine

            12.2.3.6. Ziprasidone

            12.2.3.7. Others

    12.3. Market Value Forecast, by Indication , 2017–2031

        12.3.1. Schizophrenia

        12.3.2. Dementia

        12.3.3. Bipolar Disorder

        12.3.4. Depression

        12.3.5. Drug-induced Agitation and Aggression

        12.3.6. Alcohol Withdrawal

        12.3.7. Others

    12.4. Market Value Forecast, by Route of Administration, 2017–2031

        12.4.1. Oral

        12.4.2. Intramuscular

        12.4.3. Others

    12.5. Market Value Forecast, by End-user, 2017–2031

        12.5.1. Hospitals & Ambulatory Surgical Centers

        12.5.2. Psychiatric Care Facilities

        12.5.3. Others

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Treatment Approach

        12.7.2. By Indication

        12.7.3. By Route of Administration

        12.7.4. By End-user

        12.7.5. By Country/Sub-region

13. Asia Pacific Acute Agitation and Aggression Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Treatment Approach, 2017–2031

        13.2.1. Behavioral Approaches

        13.2.2. Environmental Interventions

        13.2.3. Pharmacologic Approaches (Drugs)

            13.2.3.1. Lorazepam

            13.2.3.2. Chlorpromazine

            13.2.3.3. Quetiapine

            13.2.3.4. Droperidol

            13.2.3.5. Olanzapine

            13.2.3.6. Ziprasidone

            13.2.3.7. Others

    13.3. Market Value Forecast, by Indication, 2017–2031

        13.3.1. Schizophrenia

        13.3.2. Dementia

        13.3.3. Bipolar Disorder

        13.3.4. Depression

        13.3.5. Drug-induced Agitation and Aggression

        13.3.6. Alcohol Withdrawal

        13.3.7. Others

    13.4. Market Value Forecast, by Route of Administration , 2017–2031

        13.4.1. Oral

        13.4.2. Intramuscular

        13.4.3. Others

    13.5. Market Value Forecast, by End-user, 2017–2031

        13.5.1. Hospitals & Ambulatory Surgical Centers

        13.5.2. Psychiatric Care Facilities

        13.5.3. Others

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Treatment Approach

        13.7.2. By Indication

        13.7.3. By Route of Administration

        13.7.4. By End-user

        13.7.5. By Country/Sub-region

14. Latin America Acute Agitation and Aggression Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Treatment Approach, 2017–2031

        14.2.1. Behavioral Approaches

        14.2.2. Environmental Interventions

        14.2.3. Pharmacologic Approaches (Drugs)

            14.2.3.1. Lorazepam

            14.2.3.2. Chlorpromazine

            14.2.3.3. Quetiapine

            14.2.3.4. Droperidol

            14.2.3.5. Olanzapine

        14.2.4. Ziprasidone

            14.2.4.1. Others

    14.3. Market Value Forecast, by Indication , 2017–2031

        14.3.1. Schizophrenia

        14.3.2. Dementia

        14.3.3. Bipolar Disorder

        14.3.4. Depression

        14.3.5. Drug-induced Agitation and Aggression

        14.3.6. Alcohol Withdrawal

        14.3.7. Others

    14.4. Market Value Forecast, by Route of Administration , 2017–2031

        14.4.1. Oral

        14.4.2. Intramuscular

        14.4.3. Others

    14.5. Market Value Forecast, by End-user, 2017–2031

        14.5.1. Hospitals & Ambulatory Surgical Centers

        14.5.2. Psychiatric Care Facilities

        14.5.3. Others

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Treatment Approach

        14.7.2. By Indication

        14.7.3. By Route of Administration

        14.7.4. By End-user

        14.7.5. By Country/Sub-region

15. Middle East & Africa Acute Agitation and Aggression Treatment Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Treatment Approach, 2017–2031

        15.2.1. Behavioral Approaches

        15.2.2. Environmental Interventions

        15.2.3. Pharmacologic Approaches (Drugs)

            15.2.3.1. Lorazepam

            15.2.3.2. Chlorpromazine

            15.2.3.3. Quetiapine

            15.2.3.4. Droperidol

            15.2.3.5. Olanzapine

        15.2.4. Ziprasidone

            15.2.4.1. Others

    15.3. Market Value Forecast, by Indication, 2017–2031

        15.3.1. Schizophrenia

        15.3.2. Dementia

        15.3.3. Bipolar Disorder

        15.3.4. Depression

        15.3.5. Drug-induced Agitation and Aggression

        15.3.6. Alcohol Withdrawal

        15.3.7. Others

    15.4. Market Value Forecast, by Route of Administration, 2017–2031

        15.4.1. Oral

        15.4.2. Intramuscular

        15.4.3. Others

    15.5. Market Value Forecast, by End-user, 2017–2031

        15.5.1. Hospitals and Ambulatory Surgical Centers

        15.5.2. Psychiatric Care Facilities

        15.5.3. Others

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Treatment Approach

        15.7.2. By Indication

        15.7.3. By Route of Administration

        15.7.4. By End-user

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix (by tier and size of companies)

    16.2. Company Profiles

        16.2.1. Eli Lilly and Company

            16.2.1.1. Company Overview

            16.2.1.2. Company Financials

            16.2.1.3. Growth Strategies

            16.2.1.4. SWOT Analysis

        16.2.2. Pfizer, Inc.

            16.2.2.1. Company Overview

            16.2.2.2. Company Financials

            16.2.2.3. Growth Strategies

            16.2.2.4. SWOT Analysis

        16.2.3. Otsuka Holdings

            16.2.3.1. Company Overview

            16.2.3.2. Company Financials

            16.2.3.3. Growth Strategies

            16.2.3.4. SWOT Analysis

        16.2.4. GlaxoSmithKline

            16.2.4.1. Company Overview

            16.2.4.2. Company Financials

            16.2.4.3. Growth Strategies

            16.2.4.4. SWOT Analysis

        16.2.5. H. Lundbeck A/S

            16.2.5.1. Company Overview

            16.2.5.2. Company Financials

            16.2.5.3. Growth Strategies

            16.2.5.4. SWOT Analysis

        16.2.6. Johnson & Johnson

            16.2.6.1. Company Overview

            16.2.6.2. Company Financials

            16.2.6.3. Growth Strategies

            16.2.6.4. SWOT Analysis

        16.2.7. Teva Pharmaceutical Industries Ltd.

            16.2.7.1. Company Overview

            16.2.7.2. Company Financials

            16.2.7.3. Growth Strategies

            16.2.7.4. SWOT Analysis

        16.2.8. Amneal Pharmaceuticals LLC

            16.2.8.1. Company Overview

            16.2.8.2. Company Financials

            16.2.8.3. Growth Strategies

            16.2.8.4. SWOT Analysis

        16.2.9. Sun Pharmaceutical Industries Ltd.

            16.2.9.1. Company Overview

            16.2.9.2. Company Financials

            16.2.9.3. Growth Strategies

            16.2.9.4. SWOT Analysis

        16.2.10. F. Hoffmann-La Roche Ltd.

            16.2.10.1. Company Overview

            16.2.10.2. Company Financials

            16.2.10.3. Growth Strategies

            16.2.10.4. SWOT Analysis

        16.2.11. Bausch Health Companies, Inc.

            16.2.11.1. Company Overview

            16.2.11.2. Company Financials

            16.2.11.3. Growth Strategies

            16.2.11.4. SWOT Analysis

        16.2.12. Apotex, Inc.

            16.2.12.1. Company Overview

            16.2.12.2. Company Financials

            16.2.12.3. Growth Strategies

            16.2.12.4. SWOT Analysis

        16.2.13. Aurobindo Pharma

            16.2.13.1. Company Overview

            16.2.13.2. Company Financials

            16.2.13.3. Growth Strategies

            16.2.13.4. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis - Acute Agitation and Aggression Treatment

Table 02: Oral Medications For Clinically Significant Acute Agitation

Table 03: Parenteral Medications For Clinically Significant Acute Agitation

Table 04: Pros and Cons of Non-pharmacologic Interventions for Acute Agitation

Table 05: Pros and Cons of Pharmacologic Interventions (Different routes of administration) For Acute Agitation

Table 06: Pros and Cons of Pharmacologic Interventions (Oral) For Acute Agitation

Table 07: Pros and Cons of Pharmacologic Interventions For Acute Agitation

Table 08: Pharmacology of drugs commonly used for Acute Agitation and Aggression

Table 09: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

Table 10: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

Table 11: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 12: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 13: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 14: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 15: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

Table 16: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

Table 17: North America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 18: North America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 19: North America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 20: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 21: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

Table 22: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

Table 23: Europe Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 24: Europe Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 25: Europe Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 26: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

Table 28: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

Table 29: Asia Pacific Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 30: Asia Pacific Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 31: Asia Pacific Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 32: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 33: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

Table 34: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

Table 35: Latin America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 36: Latin America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 37: Latin America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 38: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 39: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

Table 40: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

Table 41: Middle East & Africa Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 42: Middle East & Africa Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 43: Middle East & Africa Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Acute Agitation and Aggression Treatment Market Value Share, by Treatment Approach, 2020

Figure 03: Global Acute Agitation and Aggression Treatment Market Value Share, by Route of Administration, 2020

Figure 04: Global Acute Agitation and Aggression Treatment Market Value Share, by End-user, 2020

Figure 05: Global Acute Agitation and Aggression Treatment Market Value Share, by Indication , 2020

Figure 06: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

Figure 07: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

Figure 08: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Behavioral Approaches, 2017–2031

Figure 09: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Environmental Interventions, 2017–2031

Figure 10: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Pharmacologic Approaches (Drugs), 2017–2031

Figure 11: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Lorazepam, 2017–2031

Figure 12: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Chlorpromazine, 2017–2031

Figure 13: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Quetiapine, 2017–2031

Figure 14: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Droperidol, 2017–2031

Figure 15: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Olanzapine, 2017–2031

Figure 16: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Ziprasidone, 2017–2031

Figure 17: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031

Figure 18: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 19: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 20: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Oral, 2017–2031

Figure 21: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Intramuscular, 2017–2031

Figure 22: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031

Figure 23: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

Figure 24: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

Figure 25: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Schizophrenia, 2017–2031

Figure 26: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Dementia, 2017–2031

Figure 27: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Bipolar Disorder, 2017–2031

Figure 28: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Depression , 2017–2031

Figure 29: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Drug-induced agitation and aggression, 2017–2031

Figure 30: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Alcohol withdrawal, 2017–2031

Figure 31: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031

Figure 32: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 33: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 34: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Hospitals & Ambulatory Surgical Centers, 2017–2031

Figure 35: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Psychiatric Care Facilities, 2017–2031

Figure 36: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 37: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031

Figure 38: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country, 2020 and 2031

Figure 39: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country, 2021–2031

Figure 40: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

Figure 41: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

Figure 42: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 43: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 44: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

Figure 45: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

Figure 46: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 47: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 48: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 49: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 50: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 51: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

Figure 52: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

Figure 53: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 54: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 55: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

Figure 56: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

Figure 57: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 58: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 59: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 60: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 61: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 62: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

Figure 63: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

Figure 64: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 65: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 66: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

Figure 67: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

Figure 68: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 69: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 70: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 71: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 72: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 73: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

Figure 74: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

Figure 75: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 76: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 77: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

Figure 78: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

Figure 79: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 80: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 81: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 82: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 83: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 84: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

Figure 85: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

Figure 86: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 87: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 88: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

Figure 89: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

Figure 90: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

Figure 91: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

324

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved